Luis Diaz Jr., MD, Head of the Division of Solid Tumor Oncology, with a patient.
The Division of Solid Tumor Oncology is made up of more than 100 medical oncologists who specialize in treating a broad range of common and rare solid tumors. Each is a subspecialist with deep experience in his or her area of expertise. Together, they help to coordinate the integration of surgery and radiation treatment with chemotherapy, targeted therapies, and immunotherapy across our 10 services:
- Breast Medicine Service
- Clinical Genetics Service
- Early Drug Development Service
- Gastrointestinal Oncology Service
- Genitourinary Oncology Service
- Gynecologic Medical Oncology Service
- Head and Neck Oncology Service
- Melanoma Service
- Sarcoma Medical Oncology Service
- Thoracic Oncology Service
Our division is led by Luis Diaz, Jr., MD. He is an internationally recognized physician-scientist and renowned leader in the field of oncology, with a special interest in the clinical application of cancer genetics. Dr. Diaz is credited for his pioneering efforts to provide the first definitive evidence for using circulating tumor DNA as a cancer biomarker for the screening, monitoring, and detection of occult disease and for the discovery of the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair-deficient (MMRd) tumors. He led work to establish PD-1 blockade in patients with MMRd tumors, which prompted the historic first pan-tumor FDA approval for any solid tumors with this genetic lesion. In September 2021, President Biden appointed Dr. Diaz as one of seven distinguished members of the National Cancer Advisory Board.
